Novo Nordisk's Wegovy Pill Could Register Sales of $1 Billion This Year -- Market Talk

Dow Jones

01/16

1130 GMT - Novo Nordisk's Wegovy weight-loss pill has launched, and Berenberg expects around $1 billion in sales this year. The Danish pharmaceutical company must maximize its head-start over competitor Eli Lilly and deliver a strong sales ramp up in 2026, Berenberg analysts Kerry Holford and Luisa Hector write. The bank's base case is Wegovy pill sales of $2 billion in 2027, but a blue-sky scenario could support sales of around $6 billion. Higher-than-anticipated Wegovy pill sales could offset the headwinds associated with U.S. price cuts and patent expiries in 2026, the bank adds. "We see upside to Wegovy pill consensus sales estimates." Berenberg raises its stock price target to 415 Danish kroner from 400 kroner and keeps its recommendation at buy. Shares rise 7% to 390.85 kroner. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

January 16, 2026 06:30 ET (11:30 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2603960230"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603960230\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603960230?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-16 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603960230","market":"nz","top_or_hot":-1,"title":"Novo Nordisk's Wegovy Pill Could Register Sales of $1 Billion This Year -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1130 GMT - <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s Wegovy weight-loss pill has launched, and Berenberg expects around $1 billion in sales this year. The Danish pharmaceutical company must maximize its head-start over competitor Eli Lilly and deliver a strong sales ramp up in 2026, Berenberg analysts Kerry Holford and Luisa Hector write. The bank's base case is Wegovy pill sales of $2 billion in 2027, but a blue-sky scenario could support sales of around $6 billion. Higher-than-anticipated Wegovy pill sales could offset the headwinds associated with U.S. price cuts and patent expiries in 2026, the bank adds. \"We see upside to Wegovy pill consensus sales estimates.\" Berenberg raises its stock price target to 415 Danish kroner from 400 kroner and keeps its recommendation at buy. Shares rise 7% to 390.85 kroner. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 16, 2026 06:30 ET (11:30 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk's Wegovy Pill Could Register Sales of $1 Billion This Year -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk's Wegovy Pill Could Register Sales of $1 Billion This Year -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-01-16 19:30</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1130 GMT - <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s Wegovy weight-loss pill has launched, and Berenberg expects around $1 billion in sales this year. The Danish pharmaceutical company must maximize its head-start over competitor Eli Lilly and deliver a strong sales ramp up in 2026, Berenberg analysts Kerry Holford and Luisa Hector write. The bank's base case is Wegovy pill sales of $2 billion in 2027, but a blue-sky scenario could support sales of around $6 billion. Higher-than-anticipated Wegovy pill sales could offset the headwinds associated with U.S. price cuts and patent expiries in 2026, the bank adds. \"We see upside to Wegovy pill consensus sales estimates.\" Berenberg raises its stock price target to 415 Danish kroner from 400 kroner and keeps its recommendation at buy. Shares rise 7% to 390.85 kroner. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 16, 2026 06:30 ET (11:30 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1093756168.USD","symbol_name":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603960230","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603960230","pubTimestamp":1768563000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1130 GMT - Novo Nordisk's Wegovy weight-loss pill has launched, and Berenberg expects around $1 billion in sales this year. The Danish pharmaceutical company must maximize its head-start over competitor Eli Lilly and deliver a strong sales ramp up in 2026, Berenberg analysts Kerry Holford and Luisa Hector write. The bank's base case is Wegovy pill sales of $2 billion in 2027, but a blue-sky scenario could support sales of around $6 billion. Higher-than-anticipated Wegovy pill sales could offset the headwinds associated with U.S. price cuts and patent expiries in 2026, the bank adds. \"We see upside to Wegovy pill consensus sales estimates.\" Berenberg raises its stock price target to 415 Danish kroner from 400 kroner and keeps its recommendation at buy. Shares rise 7% to 390.85 kroner. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4588":"碎股","NVO":"诺和诺德","BK4585":"ETF&股票定投概念","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4532":"文艺复兴科技持仓","BK4599":"减肥药","BK4007":"制药"},"translate_title":"诺和诺德的Wegovy药丸今年销售额可能达到10亿美元——市场讨论","themeId":"d806896b6091b132ff78b81fa73d2804","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.96},"content_text":"1130 GMT - Novo Nordisk's Wegovy weight-loss pill has launched, and Berenberg expects around $1 billion in sales this year. The Danish pharmaceutical company must maximize its head-start over competitor Eli Lilly and deliver a strong sales ramp up in 2026, Berenberg analysts Kerry Holford and Luisa Hector write. The bank's base case is Wegovy pill sales of $2 billion in 2027, but a blue-sky scenario could support sales of around $6 billion. Higher-than-anticipated Wegovy pill sales could offset the headwinds associated with U.S. price cuts and patent expiries in 2026, the bank adds. \"We see upside to Wegovy pill consensus sales estimates.\" Berenberg raises its stock price target to 415 Danish kroner from 400 kroner and keeps its recommendation at buy. Shares rise 7% to 390.85 kroner. (dominic.chopping@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 16, 2026 06:30 ET (11:30 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}